Empagliflozin confers reno-protection in acute myocardial infarction and type 2 diabetes mellitus.
Kosuke MozawaYoshiaki KubotaYu HoshikaShuhei TaraYukichi TokitaKenji YodogawaYu-Ki IwasakiTakeshi YamamotoHitoshi TakanoYayoi TsukadaKuniya AsaiMasaaki MiyamotoYasushi MiyauchiEitaro KodaniMitsunori MaruyamaJun TanabeWataru ShimizuPublished in: ESC heart failure (2021)
Empagliflozin prevented the kidney functional decline in patients with AMI and T2DM, especially those with baseline eGFR ≥ 60 mL/min/1.73 m2 . Early administration of sodium-glucose cotransporter 2 inhibitors in these patients is considered desirable for renal protection.